301 related articles for article (PubMed ID: 34505304)
41. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
Soini E; Joutseno J; Sumelahti ML
Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
[TBL] [Abstract][Full Text] [Related]
42. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
Ernst FR; Barr P; Elmor R; Wong SL
Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
[TBL] [Abstract][Full Text] [Related]
43. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
[TBL] [Abstract][Full Text] [Related]
44. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
Gold R; Arnold DL; Bar-Or A; Fox RJ; Kappos L; Mokliatchouk O; Jiang X; Lyons J; Kapadia S; Miller C
Mult Scler; 2022 Apr; 28(5):801-816. PubMed ID: 34465252
[TBL] [Abstract][Full Text] [Related]
45. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
[TBL] [Abstract][Full Text] [Related]
46. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Dorman E; Kansal AR; Sarda S
J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
[TBL] [Abstract][Full Text] [Related]
47. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Su W; Kansal A; Vicente C; Deniz B; Sarda S
J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
[TBL] [Abstract][Full Text] [Related]
48. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
49. Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.
Granqvist M; Burman J; Gunnarsson M; Lycke J; Nilsson P; Olsson T; Sundström P; Svenningsson A; Vrethem M; Frisell T; Piehl F
Mult Scler; 2020 Oct; 26(12):1532-1539. PubMed ID: 31392923
[TBL] [Abstract][Full Text] [Related]
50. Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis Portuguese Population.
Barros A; Sequeira J; de Sousa A; Parra J; Brum M; Pedrosa R; Capela C
Clin Neuropharmacol; 2020; 43(3):55-60. PubMed ID: 32384308
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
Miclea A; Leussink VI; Hartung HP; Gold R; Hoepner R
J Neurol; 2016 Aug; 263(8):1626-32. PubMed ID: 27260297
[TBL] [Abstract][Full Text] [Related]
52. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
[TBL] [Abstract][Full Text] [Related]
53. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
Delgado S; Hernandez J; Tornes L; Rammohan K
BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
[TBL] [Abstract][Full Text] [Related]
54. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
[TBL] [Abstract][Full Text] [Related]
55. Clinical effectiveness of reduced fingolimod dose in relapsing remitting multiple sclerosis-a Portuguese cohort.
Ramos-Lopes J; Batista S; Barradas P; Campelo I; Correia I; Nunes C; Macário C; Sousa L
Neurol Sci; 2021 Mar; 42(3):1039-1043. PubMed ID: 32719903
[TBL] [Abstract][Full Text] [Related]
56. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
57. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis.
Tsantes E; Curti E; Ferraro D; Lugaresi A; Baldi E; Montepietra S; Immovilli P; Simone AM; Mancinelli L; Strumia S; Vitetta F; Foschi M; Ferri C; Ferrarini C; Sola P; Granella F
Eur J Neurol; 2021 Jan; 28(1):269-277. PubMed ID: 32931130
[TBL] [Abstract][Full Text] [Related]
58. Visualizing the target estimand in comparative effectiveness studies with multiple treatments.
Simoneau G; Mitroiu M; Debray TP; Wei W; Wijn SR; Magalhães JC; Bohn J; Shen C; Pellegrini F; Moor C
J Comp Eff Res; 2024 Feb; 13(2):e230089. PubMed ID: 38261336
[No Abstract] [Full Text] [Related]
59. Dimethyl Fumarate or Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A Meta-analysis of Post-marketing Studies.
Prosperini L; Haggiag S; Ruggieri S; Tortorella C; Gasperini C
Neurotherapeutics; 2023 Sep; 20(5):1275-1283. PubMed ID: 37528262
[TBL] [Abstract][Full Text] [Related]
60. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
Earla JR; Li J; Hutton GJ; Johnson ML; Aparasu RR
Pharmacotherapy; 2023 Jun; 43(6):473-484. PubMed ID: 37157135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
